Rabbit Recombinant Monoclonal LIFR antibody. Carrier free. Suitable for WB, IP and reacts with Human, Mouse samples.
pH: 7.2 - 7.4
Constituents: 100% PBS
WB | IHC-P | ICC/IF | Flow Cyt (Intra) | IP | |
---|---|---|---|---|---|
Human | Tested | Not recommended | Not recommended | Not recommended | Tested |
Mouse | Expected | Not recommended | Not recommended | Not recommended | Not recommended |
Rat | Not recommended | Not recommended | Not recommended | Not recommended | Not recommended |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse | Dilution info Use at an assay dependent concentration. | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Rat | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human, Mouse, Rat | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human, Mouse, Rat | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human, Mouse, Rat | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Rat | Dilution info - | Notes - |
Signal-transducing molecule. May have a common pathway with IL6ST. The soluble form inhibits the biological activity of LIF by blocking its binding to receptors on target cells.
CD118, Leukemia inhibitory factor receptor, LIF receptor, LIF-R, LIFR
Rabbit Recombinant Monoclonal LIFR antibody. Carrier free. Suitable for WB, IP and reacts with Human, Mouse samples.
pH: 7.2 - 7.4
Constituents: 100% PBS
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. The carrier-free buffer and high concentration allow for increased conjugation efficiency.
This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
This product is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar® is a trademark of Fluidigm Canada Inc.
The leukemia inhibitory factor receptor also known as LIFR is a protein that plays an important role in cellular signaling. It has a mass of approximately 190-210 kDa and it is widely expressed in various tissues such as the liver muscle and bone. LIFR is a member of the interleukin 6 (IL-6) receptor family. The 'LIFR selector' refers to its ability to bind and select its specific ligand leukemia inhibitory factor (LIF) which initiates signal transduction processes. LIFR expression tends to be higher in developing tissues indicating its involvement during embryogenesis.
The leukemia inhibitory factor receptor is involved in various cellular processes including differentiation proliferation and survival. When LIF binds to LIFR it forms a complex with gp130 another receptor protein which then activates downstream signaling pathways that regulate these cellular processes. This complex formation is an important component in the maintenance of stem cell pluripotency which is important in early development. The LIFR meaning in this context is essential for translating extracellular signals into cellular responses.
The leukemia inhibitory factor receptor plays a critical role in the JAK/STAT signaling pathway. This pathway is significant for transmitting information received from extracellular chemical signals to the cell nucleus resulting in DNA transcription. LIFR closely interacts with other proteins like STAT3 and JAK1 which further propagate the signaling cascade initiated by LIF binding. Another pathway involving LIFR is the MAPK/ERK pathway a major pathway that influences cell growth and differentiation. These pathways highlight the interconnectivity of LIFR in regulating key cellular functions.
LIFR has been linked to cancer progression and osteoporosis. Abnormal LIFR signaling can lead to unchecked cellular proliferation contributing to tumorigenesis in various cancers such as liver and breast cancer. LIFR also interacts with proteins like gp130 and the aforementioned STAT3 in the cancerous context. In osteoporosis altered LIFR expression affects bone metabolism potentially leading to increased bone resorption and weakening. The role of LIFR in these diseases demonstrates its potential as a therapeutic target and its importance in maintaining normal tissue homeostasis.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
This data was developed using Anti-LIFR antibody [EPR24865-56] ab300551, the same antibody clone in a different buffer formulation.
LIFR was immunoprecipitated from 0.35 mg HeLa (human cervix adenocarcinoma epithelial cell) whole cell lysate 10 ug with Anti-LIFR antibody [EPR24865-56] ab300551 at 1/30 dilution (2ug in 0.35mg lysates). Western blot was performed on the immunoprecipitate using Anti-LIFR antibody [EPR24865-56] ab300551 at 1/1000 dilution. VeriBlot for IP secondary antibody(HRP)(VeriBlot for IP Detection Reagent (HRP) ab131366) was used at 1/5000 dilution. Lane 1: HeLa (human cervix adenocarcinoma epithelial cell) whole cell lysate 10 ug
Lane 2: abAB300551 IP in HeLa (human cervix adenocarcinoma epithelial cell) whole cell lysate
Lane 3:Rabbit monoclonal IgG (Rabbit IgG, monoclonal [EPR25A] - Isotype Control ab172730) instead of Anti-LIFR antibody [EPR24865-56] ab300551 in HeLa whole cell lysate
Blocking and dilution buffer and concentration: 5% NFDM/TBST.
Exposure time: 145 seconds
The bands beneath the target band in lane 2 are expected to be degradation products.
All lanes: Immunoprecipitation - Anti-LIFR antibody [EPR24865-56] (Anti-LIFR antibody [EPR24865-56] ab300551) at 1/1000 dilution
Lanes 1 - 2: HeLa (human cervix adenocarcinoma epithelial cell) whole cell lysate
Lane 3: Immunoprecipitation - Rabbit IgG, monoclonal [EPR25A] - Isotype Control (Rabbit IgG, monoclonal [EPR25A] - Isotype Control ab172730)
All lanes: Immunoprecipitation - VeriBlot for IP Detection Reagent (HRP) (VeriBlot for IP Detection Reagent (HRP) ab131366) at 1/5000 dilution
Exposure time: 145s
This data was developed using Anti-LIFR antibody [EPR24865-56] ab300551, the same antibody clone in a different buffer formulation.
LIFR is a glycoprotein of approximately 180 kDa and detected as a 120 kDa band after treated with Protein Deglycosylation MIX II.
Blocking Buffer and concentration: 5% NFDM/TBST
All lanes: Western blot - Anti-LIFR antibody [EPR24865-56] (Anti-LIFR antibody [EPR24865-56] ab300551) at 1/1000 dilution
Lane 1: Untreated HepG2 (human hepatocellar carcinoma epithelial cell), whole cell lysate 20 µg
Lane 2: HepG2 lysate treated with Protein Deglycosylation Mix II 20 µg
All lanes: Western blot - Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/100000 dilution
Observed band size: 180 kDa, 120 kDa
Exposure time: 3min
This data was developed using Anti-LIFR antibody [EPR24865-56] ab300551, the same antibody clone in a different buffer formulation.
Negative control: T-47D (PMID: 23001183)
Blocking Buffer and concentration: 5% NFDM/TBST
All lanes: Western blot - Anti-LIFR antibody [EPR24865-56] (Anti-LIFR antibody [EPR24865-56] ab300551) at 1/1000 dilution
Lane 1: HeLa (human cervix adenocarcinoma epithelial cell), whole cell lysate
Lane 2: PANC-1 (human pancreatic epithelioid carcinoma epithelial cell), whole cell lysate
Lane 3: T-47D (human ductal breast epithelial tumor epithelial cell), whole cell lysate
Lane 4: MDA-MB-231 (human breast adenocarcinoma epithelial cell), whole cell lysate
All lanes: Western blot - Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/100000 dilution
Observed band size: 180 kDa
Exposure time: 59s
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com